Hims & Hers is scheduled to report its quarterly earnings on Monday, offering investors crucial insight into the performance of its weight-loss business following a period of significant controversy. The company’s stock has been volatile this year, recently recovering from a public dispute with pharmaceutical firm Novo Nordisk. The upcoming report will provide clarity on the company’s performance leading up to and in the weeks following the dissolution of that partnership.
Analysts are forecasting revenue of $551.7 million, a 74% year-over-year increase, and earnings per share of $0.15. Investor focus will be on the company’s weight-loss segment. While Hims does not break out revenue from these treatments in its financial statements, it has set a $725 million annual revenue goal for the business and typically provides related figures or commentary during its earnings calls.
The earnings report covers the second quarter, a period in which Hims ceased selling direct copies of Novo Nordisk’s Ozempic and Wegovy on May 22, and its partnership with the drugmaker was officially terminated on June 23. Novo Nordisk ended the agreement—which allowed Hims to offer cash-pay versions of its brand-name drugs—because the telehealth platform also sells personalized, compounded versions of the popular weight-loss medications. Novo Nordisk recently lowered its own guidance, citing competition from compounders like Hims.
The collaboration was widely seen not as a primary revenue driver for Hims, but as a strategic move to mitigate potential litigation risk and advance the company’s long-term vision. Following the report, analysts are expected to press Hims for details on its strategy for navigating relationships with major drugmakers going forward.
Source link
